dpp-4_inhibitors DPP-4 Inhibitors Sitagliptin Trade Name: Januvia Drug Class: oral hypoglycemics Mechanism of Action: An inhibitor of dipeptidyl peptidase-4 (DPP-4), a protease that degrades the incretin GLP-1 Incretins are hormones released from the GI tract in response to nutrient ingestion Incretins potentiate glucose-stimulated insulin secretion from beta cells in the pancreas As a result of inhibiting DPP-4, increased or prolonged GLP-1 levels are able to potentiate the secretion of insulin by the pancreas The effect produced by DPP-4 inhibitors is dependent on endogenous GLP-1 levels, and produce a modest effect on GLP-1 activity compared to giving GLP-1 receptor agonists (hence DPP-4 inhibitors do not have the same impact to produce weight loss as GLP-1 agonists)
Reduced roGFP2 was obtained after a 20 min treatment with 10 mM DTT, which was subsequently removed on a ZebaTM Spin Desalting Column (Thermo Scientific)
Treatment: symptomatic therapy
Although optimizing energy metabolism therapy in patients with cardiovascular diseases is a feasible potential strategy, the underlying mechanisms of HUA-induced cardiomyocyte energy disorder are still unclear
GLP-1R ECD and Fab 3F52 was mixed 1:1 and the complex was purified by size exclusion chromatography
A study investigating the impact of resveratrol on glucose revealed that resveratrol can enhance glucose regulation and insulin sensitivity in diabetic rats (564)
